Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
February 1st 2001A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing